Opinion|Videos|March 1, 2024
BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer
Author(s)Carey K. Anders, MD
An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
5